Chemotherapy Plus Immunotherapy Slows Tumor Growth in Mice

Combination chemotherapy and immunotherapy significantly slowed tumor growth in mice with hepatocellular carcinoma (HCC), according to a study published in the Journal of Hepatology.
Although HCC is the most common form of liver cancer, treatment options are limited with only mildly improvement in survival rates. Furthermore, patients are often diagnosed in the late stages when the cancer is untreatable.
“The current drug approved by the FDA to treat hepatocellular carcinoma only increases the average survival of patients by about 3 months,” said investigator Kevin Staveley-O’Carroll, MD, PhD. “While any extension of life is valuable, our research team is developing a new therapeutic strategy that might extend and improve the quality of life of these patients.”
Immunotherapy shows promise in several cancers, such as melanoma and lung cancer, but little research has been done on the effects of immunotherapy and chemotherapy combined.
For the study, investigators treated 1 group of mice with the chemotherapy drug sunitinib, and the other with the immunotherapy antibody anti-PD-1.
Over a 4-week period, the tumors in mice treated with sunitinib grew 25 times larger, whereas the tumors in mice treated with immunotherapy grew at a slower rate and were 15 times larger.
The results of the third group administered a combination chemotherapy and immunotherapy had even slower growth, at a size that was 11 times larger.
“Our results show that a combined chemo-immunotherapeutic approach can slow tumor growth in mice more effectively than either individual treatment,” investigator Guangfu Li, PhD, DVM. “This innovation combination promotes an anti-tumor immune response and better suppresses growth of cancer. Our findings support the need for a clinical trial to test whether this could become a cost-effective treatment that could help improve the lives of patient with liver cancer.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.
The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.